Pharsight

1. Qudexy Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10363224	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (9 years from now)
US8652527	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (9 years from now)
US9555005	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (9 years from now)
US9101545	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (9 years from now)
US8889190	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (9 years from now)

Market Authorisation Date: 11 March, 2014

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg, 50 mg, 100 mg, 150 mg, and 200 mg	24 Dec, 2015	1		19 Mar, 2033	Extinguished Non-Forfeiture

Strength	Dosage	Availability
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
50MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
150MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
200MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440631	UPSHER SMITH LABS	Compositions for drug administration	May, 2026 (2 years from now)
US9283280	UPSHER SMITH LABS	Compositions for drug administration	May, 2026 (2 years from now)
US8268791	UPSHER SMITH LABS	Alkylglycoside compositions for drug administration	May, 2026 (2 years from now)
US11337962	UPSHER SMITH LABS	Formulations comprising triptan compounds	Jun, 2030 (6 years from now)
US10603305	UPSHER SMITH LABS	Formulations comprising triptan compounds	Jun, 2030 (6 years from now)
US9974770	UPSHER SMITH LABS	Formulations comprising triptan compounds	Jun, 2030 (6 years from now)
US9610280	UPSHER SMITH LABS	Formulations comprising triptan compounds	Jun, 2030 (6 years from now)
US9211282	UPSHER SMITH LABS	Formulations comprising triptan compounds	Jul, 2031 (7 years from now)

Market Authorisation Date: 25 January, 2019

Treatment: Acute treatment of migraine

Dosage: SPRAY;NASAL

Strength	Dosage	Availability
10MG/SPRAY	SPRAY;NASAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295675	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (10 years from now)
US8785426	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (10 years from now)
US9662340	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (10 years from now)

Market Authorisation Date: 04 June, 2014

Treatment: Method for transdermal delivery of testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

Strength	Dosage	Availability
12.5MG/1.25GM ACTUATION	GEL, METERED;TRANSDERMAL	Prescription
50MG/5GM PACKET	GEL;TRANSDERMAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537554	UPSHER SMITH LABS	Pharmaceutical composition for treating migraine	Jan, 2036 (12 years from now)
US11364224	UPSHER SMITH LABS	Pharmaceutical composition for treating migraine	Jan, 2036 (12 years from now)